#news #biotech Amicus ditches skin disorder drug after late-stage failure

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Amicus ditches skin disorder drug after late-stage failure .A drug for rare skin disease epidermolysis bullosa that Amicus Therapeutics acquired in a $847 million deal two years ago has failed a key phase 3 trial.

from FierceBiotech: Biotech http://ift.tt/2xy7SBV